Lumos Pharma Stock Forecast - Polynomial Regression
| LUMO Stock | USD 4.30 0.02 0.46% |
The Polynomial Regression forecasted value of Lumos Pharma on the next trading day is expected to be 4.23 with a mean absolute deviation of 0.11 and the sum of the absolute errors of 6.71. Lumos Stock Forecast is based on your current time horizon. Although Lumos Pharma's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Lumos Pharma's systematic risk associated with finding meaningful patterns of Lumos Pharma fundamentals over time.
Lumos |
Lumos Pharma Polynomial Regression Price Forecast For the 29th of November
Given 90 days horizon, the Polynomial Regression forecasted value of Lumos Pharma on the next trading day is expected to be 4.23 with a mean absolute deviation of 0.11, mean absolute percentage error of 0.02, and the sum of the absolute errors of 6.71.Please note that although there have been many attempts to predict Lumos Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Lumos Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Lumos Pharma Stock Forecast Pattern
| Backtest Lumos Pharma | Lumos Pharma Price Prediction | Buy or Sell Advice |
Lumos Pharma Forecasted Value
In the context of forecasting Lumos Pharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Lumos Pharma's downside and upside margins for the forecasting period are 0.87 and 7.58, respectively. We have considered Lumos Pharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Polynomial Regression forecasting method's relative quality and the estimations of the prediction error of Lumos Pharma stock data series using in forecasting. Note that when a statistical model is used to represent Lumos Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 114.2082 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.1101 |
| MAPE | Mean absolute percentage error | 0.0279 |
| SAE | Sum of the absolute errors | 6.7136 |
Predictive Modules for Lumos Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lumos Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Other Forecasting Options for Lumos Pharma
For every potential investor in Lumos, whether a beginner or expert, Lumos Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Lumos Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Lumos. Basic forecasting techniques help filter out the noise by identifying Lumos Pharma's price trends.Lumos Pharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lumos Pharma stock to make a market-neutral strategy. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Lumos Pharma Technical and Predictive Analytics
The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Lumos Pharma's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Lumos Pharma's current price.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Lumos Pharma Market Strength Events
Market strength indicators help investors to evaluate how Lumos Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lumos Pharma shares will generate the highest return on investment. By undertsting and applying Lumos Pharma stock market strength indicators, traders can identify Lumos Pharma entry and exit signals to maximize returns.
Lumos Pharma Risk Indicators
The analysis of Lumos Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Lumos Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting lumos stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.35 | |||
| Semi Deviation | 2.95 | |||
| Standard Deviation | 3.36 | |||
| Variance | 11.32 | |||
| Downside Variance | 9.46 | |||
| Semi Variance | 8.67 | |||
| Expected Short fall | (2.63) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock: Check out Historical Fundamental Analysis of Lumos Pharma to cross-verify your projections. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.